Topic prioritisation

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Decision date

Decision date

Prioritisation programme

Prioritisation programme

Decision

Decision

Showing 1 to 10 of 112

TitlePrioritisation programmeDecisionDecision date
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]Medicines evaluationNot selected
Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]Medicines evaluationNot selected
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12399]Medicines evaluationNot selected
Dabrafenib with trametinib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12398]Medicines evaluationNot selected
Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]Medicines evaluationNot selected
Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]Medicines evaluationNot selected
Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]Medicines evaluationNot selected
SEEG-guided radiofrequency thermocoagulation in refractory epilepsyInterventional proceduresAwaiting decision
Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]None selectedNot selected
Lanadelumab for preventing recurrent attacks of hereditary angioedema in people 2 years and over [TSID12298]None selectedNot selected

Results per page

  1. 10
  2. 25
  3. 50
  4. All